NK cytotoxicity mediated by CD16 but not by NKp30 is functional in Griscelli syndrome

被引:19
作者
Gazit, Roi
Aker, Memet
Elboim, Moran
Achdout, Hagit
Katz, Gil
Wolf, Dana G.
Katzav, Shulamit
Madelboim, Ofer [1 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel
[2] Hadassah Univ Hosp, Dept Pediat, IL-91120 Jerusalem, Israel
[3] Hadassah Med Ctr, Clin Virol Unit, Dept Clin Microbiol & Infect Dis, IL-91120 Jerusalem, Israel
[4] Hebrew Univ Jerusalem, Sch Med, Hubert H Humphrey Ctr Expt Med & Canc Res, IL-91010 Jerusalem, Israel
关键词
D O I
10.1182/blood-2006-09-047159
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Griscelli syndrome (GS) type 2 is an autosomal recessive disorder represented by pigment dilution and impaired cytotoxic T lymphocyte (CTL) activity. NK activity has been scarcely investigated in GS patients. Here, we describe a new patient, possessing a hernophagocytic syndrome with a homozygous Q118X nonsense RAB27A mutation. Single specific primer-polymerase chain reaction (SSP-PCR) was developed based on this mutation and is currently used in prenatal genetic analysis. As expected, CTLs in the patient are not functional and NK cytotoxicity against K562 or 721.221 cells is diminished. Surprisingly, however, we demonstrate that CD16-mediated killing is intact in this patient and is therefore RAB27A independent, whereas NKp30-mediated killing is impaired and is therefore RAB27A dependent. We further analyzed the signaling pathways of these 2 receptors and demonstrated phosphorylation of Vav1 after CD16 activation but not after NKp30 engagement. Thus, we identify a novel homozygous mutation in the RAB27A gene of a new GS patient, observe for the first time that some activating INK receptors function in GS patients, and demonstrate a functional dichotomy in the killing mediated by these human NK-activating receptors.
引用
收藏
页码:4306 / 4312
页数:7
相关论文
共 57 条
[1]
Arico M, 1996, LEUKEMIA, V10, P197
[2]
Tumor and viral recognition by natural killer cells receptors [J].
Arnon, Tal I. ;
Markel, Gal ;
Mandelboim, Ofer .
SEMINARS IN CANCER BIOLOGY, 2006, 16 (05) :348-358
[3]
Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus [J].
Arnon, TI ;
Achdout, H ;
Levi, O ;
Markel, G ;
Saleh, N ;
Katz, G ;
Gazit, R ;
Gonen-Gross, T ;
Hanna, J ;
Nahari, E ;
Porgador, A ;
Honigman, A ;
Plachter, B ;
Mevorach, D ;
Wolf, DG ;
Mandelboim, O .
NATURE IMMUNOLOGY, 2005, 6 (05) :515-523
[4]
Arnon TI, 2001, EUR J IMMUNOL, V31, P2680, DOI 10.1002/1521-4141(200109)31:9<2680::AID-IMMU2680>3.0.CO
[5]
2-A
[6]
Selective cross-talk among natural cytotoxicity receptors in human natural killer cells [J].
Augugliaro, R ;
Parolini, S ;
Castriconi, R ;
Marcenaro, E ;
Cantoni, C ;
Nanni, M ;
Moretta, L ;
Moretta, A ;
Bottino, C .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2003, 33 (05) :1235-1241
[7]
Characterization of the molecular defects in Rab27a, caused by RAB27A missense mutations found in patients with Griscelli syndrome [J].
Bahadoran, P ;
Busca, R ;
Chiaverini, C ;
Westbroek, W ;
Lambert, J ;
Bille, K ;
Valony, G ;
Fukuda, M ;
Naeyaert, JM ;
Ortonne, JP ;
Ballotti, R .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (13) :11386-11392
[8]
Accelerated phase in partial albinism with immunodeficiency (Griscelli syndrome): genetics and stem cell transplantation in a 2-month-old girl [J].
Baumeister, FAM ;
Stachel, D ;
Schuster, F ;
Schmid, I ;
Schaller, M ;
Wolff, H ;
Weiss, M ;
Belohradsky, BH .
EUROPEAN JOURNAL OF PEDIATRICS, 2000, 159 (1-2) :74-78
[9]
Human natural killer cell receptors and co-receptors [J].
Biassoni, R ;
Cantoni, C ;
Pende, D ;
Sivori, S ;
Parolini, S ;
Vitale, M ;
Bottino, C ;
Moretta, A .
IMMUNOLOGICAL REVIEWS, 2001, 181 :203-214
[10]
Griscelli syndrome:: Characterization of a new mutation and rescue of T-cytotoxic activity by retroviral transfer of RAB27A gene [J].
Bizario, JCS ;
Feldmann, J ;
Castro, FA ;
Ménasché, G ;
Jacob, CMA ;
Cristofani, L ;
Casella, EB ;
Voltarelli, JC ;
De Saint-Basile, G ;
Espreafico, EM .
JOURNAL OF CLINICAL IMMUNOLOGY, 2004, 24 (04) :397-410